Dr. Kirstin Claire Hirni, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5701 W 119th St Ste 220, Overland Park, KS 66209 Phone: 913-498-8787 Fax: 913-498-1744 |
Mohammad Alghalith, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10500 Quivira Rd, Overland Park, KS 66215 Phone: 913-541-3543 |
Jonathan T. Jacobs, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 5701 W 119th St Ste 419, Overland Park, KS 66209 Phone: 913-498-1444 Fax: 913-667-2759 |
Dr. Aimee Nicole Eidson, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5701 W 119th St, Suite 220, Overland Park, KS 66209 Phone: 913-498-8787 Fax: 913-498-1744 |
Dr. Annette M Hughes, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9307 W 148th Pl, Overland Park, KS 66221 Phone: 913-685-8200 |
Dr. Lary Bocquin, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 7100 College Blvd, Overland Park, KS 66210 Phone: 877-456-5506 |
Joseph Stilwill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12140 Nall Ave, Ste 200, Overland Park, KS 66209 Phone: 913-498-7409 Fax: 913-541-5028 |
Nicolle Marie Gunter, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5701 W 119th St, Ste. 220, Overland Park, KS 66209 Phone: 913-498-8787 Fax: 913-498-1744 |
News Archive
LHC Group Inc., a national provider of home health, hospice and comprehensive post-acute healthcare services, announced today that it has signed a definitive stock purchase agreement with BioScrip, Inc. to purchase two of its operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $60 million.
Nathan Urban, interim provost and the Dr. Frederick A. Schwertz Distinguished Professor of Life Sciences, and Robert Kass, professor of statistics and machine learning, have received a $930,000 grant from the National Science Foundation to apply biological and statistical neuroscience approaches in order to create a better overall understanding of how neurons encode information.
Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.
"But it's a marathon whereas you keep going, the trail gets rockier and then you lose your shoes," the 27-year-old said. "It gets harder as you get older. Things start to fail and all you can think about is how much worse it's going to get down the road."
The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.
› Verified 1 days ago